skin cancer

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

DermTech Q4 Revenues Jump 52 Percent, Miss Wall Street Estimate

Castle Biosciences Q4 Revenues Grow 45 Percent

Dermtech Q3 Revenues Rise 122 Percent

Castle Biosciences Q3 Revenues Rise 54 Percent

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

Skin Cancer Dx Firm Speclipse Raises Nearly $8M to Expand Business

Castle Biosciences Q2 Revenues Rise 79 Percent

Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic

Castle Biosciences Q1 Revenues Up 31 Percent

Castle Biosciences Q4 Revenues Down 2 Percent

DermTech Q4 Revenues Up 31 Percent

DermTech Enters Agreement With Blue Cross Blue Shield of Texas for Skin Cancer Assay

DermTech Prices $125M Public Offering of Common Stock

William Blair Initiates Coverage of Aspira Women's Health, DermTech With Outperform Ratings